13 Results for "

HDACis

" in MedChemExpress (MCE) Product Catalog:
Products (13)

13 Results for "HDACis" in MCE Product Catalog:

17
17 Publications Verification
Cat. No.: HY-15433
CAS No.: 875320-29-9
Pureté:  99.71%
Synonyms: JNJ-26481585
Target:  

HDAC Autophagy

Domaines de recherche:  

Inflammation/Immunology Cancer

Quisinostat (JNJ-26481585) is a potent and orally active pan-HDAC inhibitor (HDACi), with IC50 values ranging from 0.11 nM to 0.64 nM for HDAC1, HDAC2, HDAC4, HDAC10 and HDAC11. Quisinostat has a broad spectrum antitumoral activity . Quisinostat can induce autophagy in neuroblastoma cells .
3
3 Cited Publications
Cat. No.: HY-100719
CAS No.: 849234-64-6
Pureté:  98.74%
Target:  

HDAC HIV

Domaines de recherche:  

Infection Cardiovascular Disease

BRD-6929 is a potent, selective brain-penetrant inhibitor of class I histone deacetylase HDAC1 and HDAC2 inhibitor with IC50 of 1 nM and 8 nM, respectively. BRD-6929 shows high-affinity to HDAC1 and HDAC2 with Ki of 0.2 and 1.5 nM, respectively. BRD-6929 can be used for mood-related behavioral model research .
Cat. No.: HY-159045
CAS No.: 149648-08-8
Pureté:  99.90%
Synonyms: p-Fluoro-SAHA
Target:  

HDAC

Domaines de recherche:  

Cancer

F-SAHA is a HDAC inhibitor (HDACi) and its 18F labeled derivative can be used in tumor imaging research .
Cat. No.: HY-15433B
CAS No.: 1083078-98-1
Synonyms: JNJ26481585 hydrochloride
Target:  

HDAC Autophagy

Domaines de recherche:  

Cancer

Quisinostat (JNJ-26481585) hydrochloride is a potent and orally active pan-HDAC inhibitor (HDACi), with IC50 values ranging from 0.11 nM to 0.64 nM for HDAC1, HDAC2, HDAC4, HDAC10 and HDAC11. Quisinostat hydrochloride has a broad spectrum antitumoral activity. Quisinostat hydrochloride can induce autophagy in neuroblastoma cells .
Cat. No.: HY-149721
CAS No.: 1418293-39-6
Target:  

Apoptosis HDAC

Domaines de recherche:  

Cancer

HDAC4-IN-1 (compound 1a) is a class IIa HDACI inhibitor (IC50=0.077 μM). HDAC4-IN-1 can enhance Caspase-induced Apoptosis. HDAC4-IN-1 has anticancer activity. HDAC4-IN-1 can be used in the research of drug combination against cancer .
Cat. No.: HY-155840
CAS No.: 3059680-59-7
Pureté:  98.62%
Target:  

HDAC Apoptosis

Domaines de recherche:  

Cancer

KH16 is a potent and low nanomolar HDAC inhibitor. KH16 is against class I HDACs HDAC1, HDAC2, and HDAC3, with IC50 values ranging from 6 to 34 nM. KH16 induces cell apoptosis and is against tumor cells with various gene expression patterns .
Cat. No.: HY-118352
CAS No.: 1113025-86-7
Target:  

HDAC

Domaines de recherche:  

Neurological Disease

LB-205 is a pan-histone deacetylase inhibitor (HDACi). LB-205 can be used for the research of acute traumatic brain injury .
Cat. No.: HY-W339757
CAS No.: 321883-54-9
Domaines de recherche:  

Cancer

Dioctanoylphosphatidic acid sodium functions as a modulator of phagocyte respiratory burst, acts as a precursor to diacylglycerol and lysophosphatidic acid, and influences the phosphorylation of the mammalian target of rapamycin (mTOR) while enhancing the viability of gallbladder carcinoma cells treated with histone deacetylase inhibitors (HDACIs); it is derived from glycerophospholipid through the action of phospholipase D.
Cat. No.: HY-139795
CAS No.: 1287261-04-4
Target:  

HDAC

Domaines de recherche:  

Cancer

ZYJ-25e is a potent histone deacetylase inhibitor (HDACi) with IC50s of 0.047 μM and 0.139 μM for HDAC6 and HDAC8, respectively. ZYJ-25e is a tetrahydroisoquinoline-bearing hydroxamic acid analogue. ZYJ-25e shows marked antitumor potency in the MDA-MB231 xenograft model .
Cat. No.: HY-115885
CAS No.: 2760511-91-7
Target:  

HDAC

Domaines de recherche:  

Inflammation/Immunology Cancer

XP5 is a potent, orally active HDAC6 inhibitor with an IC50 of 31 nM. XP5 displays high antiproliferative activity against various cancer cell lines including the HDACi-resistant YCC3/7 gastric cancer cells (IC50=0.16-2.31 μM). XP5 enhances antitumor immunity when combined with a PD-L1 inhibitor in melanoma .
Cat. No.: HY-139815
CAS No.: 1314556-93-8
Target:  

HDAC

Domaines de recherche:  

Cancer

ZYJ-34c is an orally active and potent histone deacetylase inhibitor (HDACi) with IC50s of 0.056 μM and 0.146 μM for HDAC6 and HDAC8, respectively. ZYJ-34c causes G1 phase arrest in low concentration. ZYJ-34c has antiproliferative activities. ZYJ-34c exhibits antitumor potency in MDA-MB-231 and HCT116 xenograft models and possesses antimetastatic potential in a mouse hepatoma-22 (H22) pulmonary metastasis model .
Cat. No.: HY-100719R
CAS No.: 849234-64-6
Domaines de recherche:  

Infection Cardiovascular Disease

BRD-6929 (Standard) is the analytical standard of BRD-6929 (HY-100719). This product is intended for research and analytical applications. BRD-6929 is a potent, selective brain-penetrant inhibitor of class I histone deacetylase HDAC1 and HDAC2 inhibitor with IC50 of 1 nM and 8 nM, respectively. BRD-6929 shows high-affinity to HDAC1 and HDAC2 with Ki of 0.2 and 1.5 nM, respectively. BRD-6929 can be used for mood-related behavioral model research .
Cat. No.: HY-180343
CAS No.: 1795429-46-7
Target:  

HDAC

Domaines de recherche:  

Infection

FFK29 is a synthetic class II histone deacetylase inhibitor (HDACi). FFK29 can potently inhibit the growth and encystation of Acanthamoeba. FFK29 can be studied in research on protozoan and parasitic diseases .
  • 1